Ilia I. Ouspenski

Array ( [id] => 10142283 [patent_doc_number] => 09175082 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'Antigen binding proteins that bind PD-L1' [patent_app_type] => utility [patent_app_number] => 13/907685 [patent_app_country] => US [patent_app_date] => 2013-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 15 [patent_no_of_words] => 49450 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 360 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13907685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9197660 [patent_doc_number] => 20130336976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-19 [patent_title] => 'HUMAN IMMUNE THERAPIES USING A CD27 AGONIST ALONE OR IN COMBINATION WITH OTHER IMMUNE MODULATORS' [patent_app_type] => utility [patent_app_number] => 13/905436 [patent_app_country] => US [patent_app_date] => 2013-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15062 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13905436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11766953 [patent_doc_number] => 09375466 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-28 [patent_title] => 'Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics' [patent_app_type] => utility [patent_app_number] => 13/904028 [patent_app_country] => US [patent_app_date] => 2013-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 156 [patent_no_of_words] => 125418 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13904028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9294000 [patent_doc_number] => 20140037634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/901704 [patent_app_country] => US [patent_app_date] => 2013-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 49273 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13901704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173979 [patent_doc_number] => 20130315964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING OF PRODUCTION OR AMPLIFYING OF ELIMINATION OF P24 PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/894476 [patent_app_country] => US [patent_app_date] => 2013-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6340 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13894476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10182550 [patent_doc_number] => 09212224 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-15 [patent_title] => 'Antibodies that bind PD-L1 and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/892671 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 42999 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13892671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099232 [patent_doc_number] => 09856320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Cancer immunotherapy by disrupting PD-1/PD-L1 signaling' [patent_app_type] => utility [patent_app_number] => 14/400667 [patent_app_country] => US [patent_app_date] => 2013-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 56311 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14400667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191014 [patent_doc_number] => 20130330329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'B7-H7 ANTIBODIES AND METHOD OF USE' [patent_app_type] => utility [patent_app_number] => 13/891448 [patent_app_country] => US [patent_app_date] => 2013-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 17826 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13891448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147789 [patent_doc_number] => 20130302312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT' [patent_app_type] => utility [patent_app_number] => 13/889406 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26102 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9149212 [patent_doc_number] => 20130303735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT' [patent_app_type] => utility [patent_app_number] => 13/889410 [patent_app_country] => US [patent_app_date] => 2013-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26111 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13889410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267184 [patent_doc_number] => 20150152181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'ANTI-B7-H6 ANTIBODY, FUSION PROTEINS, AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/399835 [patent_app_country] => US [patent_app_date] => 2013-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7702 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14399835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9850014 [patent_doc_number] => 08951740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-10 [patent_title] => 'Genotoxicity as a biomarker for inflammation' [patent_app_type] => utility [patent_app_number] => 13/865798 [patent_app_country] => US [patent_app_date] => 2013-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 35 [patent_no_of_words] => 17378 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13865798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8976049 [patent_doc_number] => 20130209479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 13/860329 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11557 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134378 [patent_doc_number] => 20130295092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'Method for the Treatment of Neurodegenerative Diseases' [patent_app_type] => utility [patent_app_number] => 13/858667 [patent_app_country] => US [patent_app_date] => 2013-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 7190 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13858667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173920 [patent_doc_number] => 20130315905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'B7-H5, A Costimulatory Polypeptide' [patent_app_type] => utility [patent_app_number] => 13/852888 [patent_app_country] => US [patent_app_date] => 2013-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11448 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13852888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9964796 [patent_doc_number] => 09012408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis' [patent_app_type] => utility [patent_app_number] => 13/851166 [patent_app_country] => US [patent_app_date] => 2013-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 2 [patent_no_of_words] => 26116 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13851166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11486230 [patent_doc_number] => 09592289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Stable IgG4 based binding agent formulations' [patent_app_type] => utility [patent_app_number] => 13/850849 [patent_app_country] => US [patent_app_date] => 2013-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 60329 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13850849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11486230 [patent_doc_number] => 09592289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Stable IgG4 based binding agent formulations' [patent_app_type] => utility [patent_app_number] => 13/850849 [patent_app_country] => US [patent_app_date] => 2013-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 60329 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13850849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9930909 [patent_doc_number] => 20150079100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'METHODS OF TREATMENTS USING CTLA-4 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/386917 [patent_app_country] => US [patent_app_date] => 2013-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 18407 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9719713 [patent_doc_number] => 20140255411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS' [patent_app_type] => utility [patent_app_number] => 13/845420 [patent_app_country] => US [patent_app_date] => 2013-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 128 [patent_no_of_words] => 126492 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13845420 [rel_patent_id] =>[rel_patent_doc_number] =>)